ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2016, Vol. 8 ›› Issue (3): 335-337.doi: 10.3969/j.issn.1674-3865.2016.03.030

• 临床研究 • 上一篇    下一篇

沐舒坦不同使用方式在新生儿肺炎治疗中的作用

张转芳   

  1. 471200 河南 洛阳,河南省汝阳县人民医院儿科
  • 出版日期:2016-06-25 发布日期:2018-11-19
  • 作者简介:张转芳(1981-),女,主治医师。研究方向:小儿呼吸系统疾病的诊治,E-mail:1026050137@qq.com

Clinical effect of mucosolvan given in different ways in the treatment of neonatal pneumonia

ZHANG Zhuanfang   

  1. Department of Pediatrics,People's Hospital of Ruyang County,Luoyang 471200,China.
  • Online:2016-06-25 Published:2018-11-19

摘要:
目的: 分析沐舒坦不同给药途径在治疗新生儿肺炎中的临床疗效。
方法: 2012年8月至2014年10月河南省汝阳县人民医院儿科收治住院的新生儿肺炎患者86例,依据治疗方案的不同将其分为对照组和观察组各43例。对照组给予恒温箱保暖、吸氧、抗感染治疗、纠正酸碱失衡、能量合剂营养支持等常规对症治疗,同时静脉滴注沐舒坦治疗|观察组在上述治疗基础上,给予沐舒坦雾化吸入治疗。观察比较两组患儿治疗时间、临床疗效以及药物不良反应发生情况。
结果: 观察组总有效率比较差异无统计学意义(P>0.05),观察组痊愈率为95.4%(41/43),显著高于对照组79.1%(34/43),差异有统计学意义(P<0.05)。观察组治疗时间为(7.4±2.1)d,显著低于对照组(10.4±2.9)d,差异有统计学意义(P<0.05)。治疗期间两组患儿药物不良反应轻微,差异无统计学意义(P>0.05)。
结论: 沐舒坦雾化吸入配合静脉滴注使用可快速控制患儿临床症状,缩短治疗时间,提高治愈率,且患儿无明显不良反应,安全性较好。

关键词: 肺炎, 沐舒坦, 静脉滴注, 雾化吸入, 婴儿, 新生

Abstract:
Objective: To investigate the clinical effect of mucosolvan given in different ways in the treatment of neonatal pneumonia.
Methods: Totally 86 cases of neonatal pneumonia were selected in the Pediatric Department of People′s Hospital of Ruyang County from Aug.2012 to Oct.2014,and according to the different treatment options they were divided into control group and observation group,43 cases in each group.The control group was given constant temperature incubator,oxygen,anti-infection,correction of acid-base imbalance,energy mixture of nutritional support and other conventional symptomatic treatment.At the same time,intravenous infusion of mucosolvan treatment was given.The observation group was given mucosolvan inhalation therapy in addition to the above treatment.The treatment time,clinical efficacy and adverse drug reactions were observed and compared between the two groups.
Results: There was no significant difference in the total effective rate between the two groups(P>0.05).The cure rate of observation group was 95.4%(41/43),significantly higher than that of the control group[79.1%(34/43)],the difference being statistically significant(P<0.05).In the observation group,treatment time was(7.4±2.1)d,significantly shorter than the control group(10.4±2.9)d,the difference being statistically significant (P<0.05).Adverse drug reactions were mild in the two groups during the treatment period,the difference being not statistically significant(P>0.05).
Conclusion: Mucosolvan aerosol inhalation combined with intravenous use can control clinical symptoms quickly,shorten the treatment time and improve the cure rate.It is safer and has no obvious adverse drug reactions.

Key words: Pneumonia, Mucosolvan, Intravenous infusion, Atomizing inhalation, Infant,newborn